Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129 | 0.93 | GPR84 (0.45) | ALDH1A1MAPK1GPR84KMT2API4KA | |
| SCHEMBL9081842 | 0.93 | GPR84 (0.45) | ALDH1A1MAPK1GPR84KMT2API4KA | |
| SCHEMBL606 | 0.89 | PDK2 (0.37) | GPR84KDM4EMEN1KMT2A | |
| Succinchlorimide SCHEMBL9385981 | 0.85 | GPR84 (0.35) | ALDH1A1MAPK1GPR84PARP1GSK3B | |
| SCHEMBL8790906 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1GPR84PARP1GSK3B | |
| SCHEMBL3027998 | 0.81 | GAA (0.39) | KDM4EMEN1KMT2A | |
| SCHEMBL4356446 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPK1GPR84PARP1GSK3B | |
| SCHEMBL9592755 | 0.79 | GPR84 (0.37) | ALDH1A1MAPK1GPR84PARP1GSK3B | |
| SCHEMBL9083256 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPK1GPR84PARP1GSK3B | |
| SCHEMBL8435741 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPK1GPR84PARP1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215691-A | Ion modified liquid and preparation method and application thereof | 佛山市麦克罗美的滤芯设备制造有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-117174859-A | Low-cost high-capacity coal-based hard carbon composite material and preparation method and application thereof | 常州烯源谷新材料科技有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-116410139-A | Preparation method of losartan impurity | 润都制药(荆门)有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-01-30 | — | — | US | claimed |
| CN-101328167-B | Preparation method of losartan | BEIJING SECOND PHARMACEUTICAL CO LTD | 2012-04-25 | — | — | CN | claimed |
| CN-1915990-B | Method for preparingLosartan | HAIZHENG PHARMACEUTICAL IND CO LTD ZHEJIANG | 2011-07-13 | — | — | CN | claimed |
| US-20090056795-A1 | ELECTROLYTE FOR SOLAR CELL AND SOLAR CELL HAVING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2009-03-05 | — | — | US | claimed |
| CN-1915990-A | Method for preparingLosartan | HAIZHENG PHARMACEUTICAL IND CO (CN) | 2007-02-21 | — | — | CN | claimed |
| JP-2007501770-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1660463-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | Dipharma S.p.A. (IT) | 2006-05-31 | — | — | EP | claimed |
| WO-2005014560-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | DIPHARMA S.P.A. (IT) | 2005-02-17 | — | — | WO | claimed |
| JP-7053524-A | — | — | None | — | — | JP | disclosed |
| CN-119215691-A | Ion modified liquid and preparation method and application thereof | 佛山市麦克罗美的滤芯设备制造有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-117174859-A | Low-cost high-capacity coal-based hard carbon composite material and preparation method and application thereof | 常州烯源谷新材料科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-117143023-A | Preparation method of imidazole aldehyde and recrystallization process | 云南云天化股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| EP-0028833-B1 | IMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-01-25 | — | — | EP | disclosed |
| US-4340598-A | Hypotensive imidazole derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-07-20 | — | — | US | disclosed |
| EP-0028833-A2 | Imidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PLCB3, INPP5D | ALDH1A1 4053/4885MAPK1 1786/4885GPR84 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.